Literature DB >> 30347042

The Use of "Trend" Statements to Describe Statistically Nonsignificant Results in the Oncology Literature.

Kevin T Nead1, Mackenzie R Wehner2, Nandita Mitra3.   

Abstract

Mesh：

Year:  2018        PMID： 30347042      PMCID： PMC6440716          DOI： 10.1001/jamaoncol.2018.4524

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  4 in total

1.  Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.

Authors:  Annette M Staiger; Marita Ziepert; Heike Horn; David W Scott; Thomas F E Barth; Heinz-Wolfram Bernd; Alfred C Feller; Wolfram Klapper; Monika Szczepanowski; Michael Hummel; Harald Stein; Dido Lenze; Martin-Leo Hansmann; Sylvia Hartmann; Peter Möller; Sergio Cogliatti; Georg Lenz; Lorenz Trümper; Markus Löffler; Norbert Schmitz; Michael Pfreundschuh; Andreas Rosenwald; German Ott
Journal:  J Clin Oncol       Date:  2017-05-19       Impact factor: 44.544

2.  CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.

Authors:  Marianne Sinn; Marcus Bahra; Torsten Liersch; Klaus Gellert; Helmut Messmann; Wolf Bechstein; Dirk Waldschmidt; Lutz Jacobasch; Martin Wilhelm; Bettina M Rau; Robert Grützmann; Arndt Weinmann; Georg Maschmeyer; Uwe Pelzer; Jens M Stieler; Jana K Striefler; Michael Ghadimi; Sven Bischoff; Bernd Dörken; Helmut Oettle; Hanno Riess
Journal:  J Clin Oncol       Date:  2017-08-17       Impact factor: 44.544

3.  Primary Breast Lymphoma in the United States: 1975-2013.

Authors:  Alexandra Thomas; Brian K Link; Sean Altekruse; Paul A Romitti; Mary C Schroeder
Journal:  J Natl Cancer Inst       Date:  2017-06-01       Impact factor: 13.506

4.  Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score.

Authors:  Andrew X Zhu; Ari David Baron; Peter Malfertheiner; Masatoshi Kudo; Seiji Kawazoe; Denis Pezet; Florian Weissinger; Giovanni Brandi; Carlo A Barone; Takuji Okusaka; Yoshiyuki Wada; Joon Oh Park; Baek-Yeol Ryoo; Jae Yong Cho; Hyun Cheol Chung; Chung-Pin Li; Chia-Jui Yen; Kuan-Der Lee; Shao-Chun Chang; Ling Yang; Paolo B Abada; Ian Chau
Journal:  JAMA Oncol       Date:  2017-02-01       Impact factor: 31.777
  4 in total
  5 in total

1.  The Use of Not-Negative Conclusions to Describe Results of Formally Negative Trials Presented at Oncology Meetings.

Authors:  Massimo Di Maio; Marco Audisio; Claudia Cardone; Emmanuele De Luca; Piera Gargiulo; Clizia Zichi; Francesco Perrone
Journal:  JAMA Oncol       Date:  2020-06-01       Impact factor: 31.777

2.  The Predictive Individual Effect for Survival Data.

Authors:  Beat Neuenschwander; Satrajit Roychoudhury; Simon Wandel; Kannan Natarajan; Emmanuel Zuber
Journal:  Ther Innov Regul Sci       Date:  2022-03-16       Impact factor: 1.778

Review 3.  "Petite" p value: A Researchers' Dream! Readers, Beware of the Pit ….

Authors:  Sharada Mailankody; Jyoti Bajpai; Sudeep Gupta
Journal:  Indian J Crit Care Med       Date:  2020-04

4.  Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors.

Authors:  Samuel A Funt; Deaglan J McHugh; Stephanie Tsai; Andrea Knezevic; Devon O'Donnell; Sujata Patil; Deborah Silber; Maria Bromberg; Maryann Carousso; Victor E Reuter; Brett S Carver; Joel Sheinfeld; Robert J Motzer; Dean F Bajorin; George J Bosl; Darren R Feldman
Journal:  Oncologist       Date:  2021-03-12

5.  Analysis of 567,758 randomized controlled trials published over 30 years reveals trends in phrases used to discuss results that do not reach statistical significance.

Authors:  Willem M Otte; Christiaan H Vinkers; Philippe C Habets; David G P van IJzendoorn; Joeri K Tijdink
Journal:  PLoS Biol       Date:  2022-02-18       Impact factor: 8.029
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.